Ovarian Cancer

Common Questions & Answers
Only around 20 percent of ovarian cancers are found at an early stage. This is because this type of cancer rarely causes symptoms and there are currently no reliable screening tests for the disease.
The most common type of ovarian cancer is called epithelial ovarian cancer, which develops in the epithelial cells on the surface of the ovary, fallopian tubes, or the peritoneum (abdominal cavity). Around 90 percent of ovarian cancers originate with epithelial tumors.
Combination birth control pills — those that contain estrogen and progestin — have been found to help prevent ovarian cancer. Removal of the ovaries (oophorectomy) or of the ovaries and the fallopian tubes (salpingo-oopherectomy) is another option in women who aren’t planning to have children or are past childbearing age.

Tingting Tan, MD, PhD
Medical Reviewer
Tingting Tan, MD, PhD, is a medical oncologist at City of Hope National Medical Center.
Dr. Tan's research has been published in multiple medical and scientific journals, including Oncologists, Cancer Cell, and Genes and Development.
A graduate of the Beijing Medical University, Tan holds an M.D. from Peking University Health Science Center and a Ph.D. from Rutgers University. Her training includes fellowships at the University of California San Francisco Cancer Research Institute and the Fox Chase Cancer Center at Temple University.

Walter Tsang, MD
Medical Reviewer
Outside of his busy clinical practice, Tsang has taught various courses at UCLA Center for East West Medicine, Loma Linda University, and California University of Science and Medicine. He is passionate about health education and started an online seminar program to teach cancer survivors about nutrition, exercise, stress management, sleep health, and complementary healing methods. Over the years, he has given many presentations on integrative oncology and lifestyle medicine at community events. In addition, he was the founding co-chair of a lifestyle medicine cancer interest group, which promoted integrative medicine education and collaborations among oncology professionals.
Tsang is an active member of American Society of Clinical Oncology, Society for Integrative Oncology, and American College of Lifestyle Medicine. He currently practices at several locations in Southern California. His goal is to transform cancer care in the community, making it more integrative, person-centered, cost-effective and sustainable for the future.
Lindsey Marcellin, MD, MPH
Medical Reviewer
Lindsey Marcellin, MD, MPH is an internal medicine specialist with extensive clinical experience in multiple practice settings. Dr. Marcellin is a past medical director of both fee-for-service and community free clinics. She is a director and medical team leader for Solar Light for Africa, Ltd., a non-profit group providing solar energy systems to health care facilities in Africa, and has led three medical assistance teams to Uganda. She graduated from Eastern Virginia Medical School, and completed post-graduate training at Georgetown University. She has a master's degree in public health from Johns Hopkins Bloomberg School of Public Health, with a concentration in infectious diseases and international health. She writes on and reviews a wide range of medical and public health issues.

Thomas Urban Marron, MD, PhD
Medical Reviewer
Dr. Marron received his bachelor's degree in human biology from the University of Virginia in Charlottesville in 2005, his PhD in immunology from the Icahn School of Medicine in 2010, and his MD from the Icahn School of Medicine in 2012. He remained at Mount Sinai Hospital for his internal medicine residency, which he completed in 2014, and for his clinical fellowships in hematology and medical oncology, which he completed in 2017.

Conor Steuer, MD
Medical Reviewer
Conor E. Steuer, MD, is medical oncologist specializing in the care of aerodigestive cancers, mesothelioma, and thymic malignancies and an assistant professor in the department of hematology and medical oncology at the Emory University School of Medicine in Atlanta. He joined the clinical staff at Emory's Winship Cancer Institute as a practicing physician in July 2015. He currently serves as chair of the Lung and Aerodigestive Malignancies Working Group and is a member of the Discovery and Developmental Therapeutics Research Program at Winship.
Dr. Steuer received his medical degree from the New York University School of Medicine in 2009. He completed his postdoctoral training as a fellow in the department of hematology and medical oncology at the Emory University School of Medicine, where he was chief fellow in his final year.
He has been active in research including in clinical trial development, database analyses, and investigation of molecular biomarkers. He is interested in investigating the molecular biology and genomics of thoracic and head and neck tumors in order to be able to further the care of these patient populations. Additionally, he has taken an interest in utilizing national databases to perform clinical outcomes research, as well as further investigate rare forms of thoracic cancers.
Steuer's work has been published in many leading journals, such as Cancer, the Journal of Thoracic Oncology, and Lung Cancer, and has been presented at multiple international conferences.

Daniel Landau, MD
Medical Reviewer
Daniel Landau, MD, is a distinguished board-certified hematologist-oncologist with a career that has spanned two eminent institutions: the Orlando Health Cancer Institute and the Medical University of South Carolina. With a specialized interest in genitourinary oncology and hematology, he has been at the forefront of managing both benign and malignant conditions.
Dr. Landau is a pioneering figure in integrating advanced technology into oncology, having served as a director of telemedicine services. Under his leadership, multiple innovative systems have been designed and piloted, all with a singular focus: enhancing the patient experience.
Beyond his clinical and technological endeavors, Landau is deeply committed to medical education. He has dedicated significant time and expertise to nurturing the skills of medical students, residents, and fellows, ensuring that the flame of knowledge and compassion burns bright in the next generation of oncologists.

Ryland J. Gore, MD, MPH
Medical Reviewer
In addition to her professional responsibilities, Gore previously served on the board of directors for Every Woman Works, an Atlanta-based nonprofit organization whose mission is to empower women and help them transition into independence and stability from common setbacks. Gore served as the chairwoman of the American Cancer Society’s Making Strides Against Breast Cancer campaign in Atlanta for three years (2019 to 2021). She is currently the co-director of Nth Dimensions’ Strategic Mentoring Program and the alumni board chair of the Summer Health Professions Educational Program (SHPEP), which is a collaborative effort by the Robert Wood Johnson Foundation, Association of American Medical Colleges, and the American Dental Education Association.
Gore is a highly sought after speaker, consultant, and lecturer on breast cancer and breast health, as well as women’s empowerment topics.
- Ovarian Cancer. Centers for Disease Control and Prevention. September 12, 2024.
- Tests for Ovarian Cancer. American Cancer Society. November 17, 2022.
- Treating Ovarian Cancer. American Cancer Society.
ALL OVARIAN CANCER ARTICLES









